600056
XSHG
Market cap1.85bUSD
Nov 20, Last price
8.24CNY
1D
-2.37%
1Q
-10.43%
Jan 2017
-39.37%
Name
China Medicine Health Industry Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
China Meheco Group Co., Ltd. functions as a pharmaceutical company with a presence across both domestic Chinese and international markets. The enterprise's primary operations involve the import and export of various national Chinese medicines and health-related items, as well as the production and commercial distribution of pharmaceutical and wellness solutions. It also oversees a network of retail pharmacies. The company's extensive product catalog includes bulk pharmaceutical chemicals, such as those from antibiotic fermentation and chemical synthesis, along with finished dosage forms like tablets, injections, and capsules. It supplies a broad range of antibiotics and medications specifically formulated for cardiovascular, cerebrovascular, chronic, and diabetic conditions. Additionally, its offerings encompass antiviral and anti-infectious agents, gastrointestinal remedies, non-steroidal anti-inflammatory drugs, anti-allergic treatments, specialized botanical products, Western medicine preparations, traditional Chinese patent medicines, processed herbal ingredients, medical equipment and supplies, biological products and their raw materials, various chemical raw materials, and nutritional and general healthcare products. Furthermore, China Meheco Group Co., Ltd. engages in the cultivation, processing, warehousing, and transportation of medicinal herbs, including prominent examples such as ginseng, licorice, ephedra, rhubarb, rheum officinale, astragalus membranaceus, scutellaria baicalensis, and fennel. The company, established in 1984, is headquartered in Beijing, China.
Key people
Guang Yang
Chairman of the Board · since 2024
Xiaohong Ge
Chief Accounting Officer · since 2023
Jian Zhang
Chief Compliance Officer, General Counsel · since 2022
Peng Zhang
Deputy General Manager · since 2025
Jianxiong Chen
Deputy General Manager · since 2025
Heping Lu
Assistant to General Manager · since 2022
Huibo Zhang
Assistant to General Manager · since 2021
Jinghua Yuan
Secretary of the Board · since 2023
Huidong Hu
General Manager, Director · since 2022
Zhen Pan
Director · since 2025
Chaoyin Tong
Director · since 2021
Xin Yang
Director · since 2025
Zhiyong Li
Independent Director · since 2023
Independent Director · since 2024
Yonghong Yan
Independent Director · since 2023
Xinmin Zhang
Independent Director · since 2022
Headquarters & legal address
北京市东城区光明中街18号
东城区, BJ 100000
CN
东城区, BJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||